文献速递乳腺癌放疗放疗物理与技术

磁共振引导俯卧位术前加速部分乳腺照射在临床I期激素敏感乳腺癌中的可行性研究

Use of Magnetic Resonance Imaging to Guide Preoperative Accelerated Partial Breast Irradiation in the Prone Position and Treatment Response in Clinical Stage 1 Hormone Sensitive Breast Cancer: A Phase 1/2 Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-12-06

这项1/2期前瞻性研究纳入19例临床IA期ER+/PR+/HER2-乳腺癌患者,采用俯卧位MRI/CT引导术前加速部分乳腺照射(pAPBI,3850 cGy/10次,每日两次),4周后MRI评估肿瘤反应,4-6周后行肿块切除术。中位随访73.8个月,10.5%达病理完全缓解,另36.8%降期,MRI检测的肿瘤反应与病理反应显著相关(P=.03),局部控制率95%,无病生存率89.5%。

要点

  • 俯卧位MRI/CT引导pAPBI技术可行,患者均完成计划并接受手术。
  • pAPBI后近半数患者出现影像和病理肿瘤反应。
  • 中位随访73.8个月,局部控制95%,无病生存89.5%。

核心结论

  • 采用同一俯卧位平台可成功完成CT模拟、MRI采集和pAPBI,随后行肿块切除术。
  • 近半数患者对pAPBI表现出影像学和病理学肿瘤反应。

研究设计与样本

  • 前瞻性1/2期可行性研究,纳入19例年龄>50岁、临床IA期ER+乳腺癌拟行肿块切除术的患者。
  • 腋窝超声和MRI确认临床淋巴结阴性。
  • 计划CT、MRI和pAPBI(3850 cGy分10次,每日两次)使用同一俯卧位固定平台。
  • APBI后4周复查MRI定量测量肿瘤反应,pAPBI后4-6周行肿块切除术。
  • 采用Simon两阶段设计,前19例患者入组后评估可行性。

主要发现

  • 19例临床IA期ER+/PR+/HER2-乳腺癌患者完成pAPBI及后续手术和内分泌治疗,中位年龄65岁(范围51-78岁)。
  • 中位随访73.8个月(IQR 58.6-82.5个月),中位临床肿瘤大小0.9 cm(IQR 0.8-1.6 cm)。
  • 10.5%(2例)达病理完全缓解,另36.8%(7例)降期。
  • MRI检测的肿瘤反应与病理肿瘤反应显著相关(P=.03)。
  • 89.5%(17例)患者美容效果评为优/良;尽管3例最终病理腋窝淋巴结发现宏转移(腋窝超声阴性),局部控制率95%,无病生存率89.5%。

临床怎么用

  • 俯卧位MRI/CT引导pAPBI技术可行,可用于术前部分乳腺照射的精确靶向和疗效评估。
  • 该技术可推广至俯卧位立体定向体部放疗或瘤床补量放疗。

局限性

  • 样本量小(19例),为可行性研究。
  • 随访时间有限(中位73.8个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The challenges of postoperative accelerated partial breast irradiation (APBI) include targeting inaccuracies and inability to measure tumor response. We hypothesized that the tumor could be targeted with preoperative APBI (pAPBI) using magnetic resonance imaging (MRI) in prone position with our established prone breast technique. This feasibility study aimed to assess the accuracy and tumor response of pAPBI using our MRI/computed tomography (CT)-guided prone technology. METHODS AND MATERIALS: This prospective study enrolled patients aged >50 years with clinical stage IA ER+ breast cancer intending lumpectomy. Axillary ultrasound and MRI confirmed clinically negative nodes. Planning CT, MRI, and pAPBI (3850 cGy in 10 fractions twice a day) used the same prone immobilization platform. Another MRI was obtained 4 weeks after APBI to quantitatively measure tumor response. Lumpectomy was performed 4 to 6 weeks after pAPBI. Simon's 2-stage design required assessment after accrual of the first 19 patients for feasibility. RESULTS: Nineteen patients with clinical stage IA ER+/PR+/HER2- breast cancer with median age of 65 years (range, 51-78 years) completed pAPBI followed by lumpectomy and endocrine therapy. Median follow-up was 73.8 months (IQR, 58.6-82.5 months). Median clinical tumor size was 0.9 cm (IQR, 0.8-1.6 cm). There was complete pathologic response in 10.5% (2) patients and another 36.8% (7) were downstaged after pAPBI. MRI-detected tumor response significantly correlated with tumor response on pathology (P = .03). Cosmesis was rated as excellent/good in 89.5% (17) patients. Although 3 patients had macrometastases in nodes on final pathology despite a negative axillary ultrasound, local control was 95% and disease-free survival was 89.5% at a median follow-up of 73.8 months. CONCLUSIONS: Using the same prone platform, patients successfully underwent CT simulation, MRI acquisition, and pAPBI followed by lumpectomy. Nearly half of patients demonstrated tumor response to pAPBI on imaging and pathology. Further utilization of this technology can be highly applicable to the delivery of pAPBI, stereotactic body radiation therapy, or tumor bed boost radiation in the prone position.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Beyer S, Hawley J, Gokun Y, et al. Use of Magnetic Resonance Imaging to Guide Preoperative Accelerated Partial Breast Irradiation in the Prone Position and Treatment Response in Clinical Stage 1 Hormone Sensitive Breast Cancer: A Phase 1/2 Study. Int J Radiat Oncol Biol Phys. 2025. PMID: 41360291. doi:10.1016/j.ijrobp.2025.11.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。